tbuckley/cabot-search huggingface dataset:
Mitochondria-Rich Extracellular Vesicles Rescue Patient-Specific Cardiomyocytes From Doxorubicin Injury
Authors: Connor G. O’Brien, Mehmet Ozgun Ozen, Gentaro Ikeda, Evgeniya Vaskova, Ji Hye Jung, Nathan Bayardo, Michelle Rai Santoso, Liye Shi, Christine Wahlquist, Zewen Jiang, Yunshin Jung, Yitian Zeng, Elizabeth Egan, Robert Sinclair, Adrian Gee, Ronald Witteles, Mark Mercola, Katrin J. Svensson, Utkan Demirci, Phillip C. Yang
Journal: JACC CardioOncology (2021)

Anthracycline-induced cardiomyopathy (AIC) is a significant source of morbidity and mortality in cancer survivors. The role of mesenchymal stem cells (MSCs) in treating AIC was evaluated in the SENECA trial, a Phase 1 National Heart, Lung, and Blood Institute-sponsored study, but the mechanisms underpinning efficacy in human tissue need clarification.The purpose of this study was to perform an in vitro clinical trial evaluating the efficacy and putative mechanisms of SENECA trial-specific MSCs in treating doxorubicin (DOX) injury, using patient-specific induced pluripotent stem cell-derived cardiomyocytes (iCMs) generated from SENECA patients.Patient-specific iCMs were injured with 1 μmol/L DOX for 24 hours, treated with extracellular vesicles (EVs) from MSCs by either coculture or direct incubation and then assessed for viability and markers of improved cellular physiology. MSC-derived EVs were separated into large extracellular vesicles (L-EVs) (>200 nm) and small EVs (<220nm) using a novel filtration system.iCMs cocultured with MSCs in a transwell system demonstrated improved iCM viability and attenuated apoptosis. L-EVs but not small EVs recapitulated this therapeutic effect. L-EVs were found to be enriched in mitochondria, which were shown to be taken up by iCMs. iCMs treated with L-EVs demonstrated improved contractility, reactive oxygen species production, ATP production, and mitochondrial biogenesis. Inhibiting L-EV mitochondrial function with 1-methyl-4-phenylpyridinium attenuated efficacy.L-EV-mediated mitochondrial transfer mitigates DOX injury in patient-specific iCMs. Although SENECA was not designed to test MSC efficacy, consistent tendencies toward a positive effect were observed across endpoints. Our results suggest a mechanism by which MSCs may improve cardiovascular performance in AIC independent of regeneration, which could inform future trial design evaluating the therapeutic potential of MSCs.
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib
Authors: Adam S. Kittai, Cecelia Miller, Daniel Goldstein, Ying Huang, Lynne V. Abruzzo, Kyle Beckwith, Seema A. Bhat, David A. Bond, Michael R. Grever, Nyla A. Heerema, Kerry A. Rogers, Amy S. Ruppert, John C. Byrd, Jennifer A. Woyach
Journal: Blood (2021)
Abstract 15282: Quality of Life and Exercise Performance in Low Risk Hypertrophic Cardiomyopathy: VANISH Ancillary Study
Authors: Danielle Burstein, Antara Mondal, Jungwon Min, Jen Faerber, Joseph W Rossano, Carolyn Ho, Renee E Margossian, Steven D Colan, Matthew J O’Connor, Jonathan H Soslow, Larry W Markham, Thomas Disalvo, Harry M Lever, Kenneth G Zahka, Ivan Wilmot, Juli Sublett, Mark W Russell, Sharlene Day, Amit Patel, Anne M Murphy, Charles E Canter, Richard G Bach, Luisa Mestroni, Matthew Taylor, Euan A Ashley, Matthew T Wheeler, Lee Benson, Anjali T Owens, Elfriede Pahl, Philip Thrush, Alexandre D Pereira, Henning Bundgaard, Anna Axelsson, Kimberly Y Lin
Journal: Circulation (2019)

Introduction: Limited data exists describing impact of hypertrophic cardiomyopathy (HCM) on quality of life (QOL) or exercise performance. The Valsartan for Attenuating Disease in Early Sarcomeric ...
LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC
Authors: Xinyi Qian, Juze Yang, Qiongzi Qiu, Xufan Li, Chengxi Jiang, Jia Li, Liangliang Dong, Kejing Ying, Bingjian Lu, Enguo Chen, Pengyuan Liu, Yan Lu
Journal: Journal of Hematology & Oncology (2021)

Abstract Background Long non-coding RNAs (lncRNAs) are important epigenetic regulators, which play critical roles in diverse physiological and pathological processes. However, the regulatory mechanism of lncRNAs in lung carcinogenesis remains elusive. Here, we characterized a novel oncogenic lncRNA, designated as Lung Cancer Associated Transcript 3 (LCAT3). Methods We predicted and validated LCAT3 by analyzing RNA-sequencing (RNA-seq) data of lung cancer tissues from TCGA. Methylated RNA immunoprecipitation was performed to assess m6A modification on LCAT3. The LCAT3-FUBP1-MYC axis was assessed by dual-luciferase reporter, RNA immunoprecipitation and Chromatin immunoprecipitation assays. Signaling pathways altered by LCAT3 knockdown were identified using RNA-seq. Furthermore, the mechanism of LCAT3 was investigated using loss-of-function and gain-of-function assays in vivo and in vitro. Results LCAT3 was found to be up-regulated in lung adenocarcinomas (LUAD), and its over-expression was associated with the poor prognosis of LUAD patients. LCAT3 upregulation is attributable to N6-methyladenosine (m6A) modification mediated by methyltransferase like 3 (METTL3), leading to LCAT3 stabilization. Biologically, loss-of-function assays revealed that LCAT3 knockdown significantly suppressed lung cancer cell proliferation, migration and invasion in vitro, and inhibited tumor growth and metastasis in vivo. LCAT3 knockdown induced cell cycle arrest at the G1 phase. Mechanistically, LCAT3 recruited Far Upstream Element Binding Protein 1 (FUBP1) to the MYC far-upstream element (FUSE) sequence, thereby activating MYC transcription to promote proliferation, survival, invasion and metastasis of lung cancer cells. Conclusions Taken together, we identified and characterized LCAT3 as a novel oncogenic lncRNA in the lung, and validated the LCAT3-FUBP1-MYC axis as a potential therapeutic target for LUAD.
Active surveillance characterizes human intratumoral T cell exhaustion
Authors: Ran You, Jordan Artichoker, Adam Fries, Austin W. Edwards, Alexis J. Combes, Gabriella C. Reeder, Bushra Samad, Matthew F. Krummel
Journal: Journal of Clinical Investigation (2021)

Intratumoral T cells that might otherwise control tumors are often identified in an "exhausted" state, defined by specific epigenetic modifications and upregulation of genes such as CD38, cytotoxic T-lymphocyte-associated protein 4 (CTLA4), and programmed cell death 1 (PD1). Although the term might imply inactivity, there has been little study of this state at the phenotypic level in tumors to understand the extent of their incapacitation. Starting with the observation that T cells move more quickly through mouse tumors the longer they reside there and progress toward exhaustion, we developed a nonstimulatory, live-biopsy method for the real-time study of T cell behavior within individual patient tumors. Using 2-photon microscopy, we studied native CD8+ T cell interaction with antigen-presenting cells (APCs) and cancer cells in different microniches of human tumors and found that T cell speed was variable by region and by patient and was inversely correlated with local tumor density. Across a range of tumor types, we found a strong relationship between CD8+ T cell motility and the exhausted T cell state that corresponded with our observations made in mouse models in which exhausted T cells moved faster. Our study demonstrates T cell dynamic states in individual human tumors and supports the existence of an active program in "exhausted" T cells that extends beyond incapacitating them.
Abstract 39: Intrathoracic Pressure Regulation During and After Cardiopulmonary Resuscitation: A Feasibility Study
Authors: Nicolas Segal, Brent Parquette, Demetris Yannopoulos, Jonathon Ziehr, David Lindstrom
Journal: Circulation (2011)

Objective: Reduction of intrathoracic pressures to -10 cm H2O during the decompression phase of cardiopulmonary resuscitation (CPR) increases cardiac preload, lowers intracranial pressures, and increases circulation and survival rates in pigs undergoing standard CPR. In this proof of concept study, we tested the hypothesis that augmentation of negative intrathoracic pressure during standard (S) CPR with intrathoracic pressure regulation (IPR) providing continuous negative intrathoracic pressure of -10 cm H2O between positive pressure ventilations will improve circulation, using end tidal (ET) CO2 as a non-invasive surrogate of organ perfusion, in patients receiving S-CPR. Methods: In this first clinical evaluation of IPR (CirQLatorTM, Advanced Circulatory Systems Inc, Roseville, MN) paramedic supervisors in Toledo OH performed CPR, applied IPR in 12 adult patients, and measured ETCO2, blood pressure and O2 saturation upon return of spontaneous circulation (ROSC) rates. IPR was continued after ROSC to help maintain perfusion. Values are expressed as mean ± SEM and statistical significance was determined by a paired Student's t-test. ETCO2 and blood pressure are expressed in mmHg. Results: IPR was used together with S-CPR to treat cardiac arrest in 12 patients: mean age 64 ± 3; 4 were male and the initial recorded rhythms were ventricular fibrillation (n=2), pulseless electrical activity (n=3), and asystole (n=7). Time from the initial 911 call to IPR application was 16±1 min. Initial ETCO2 when IPR was applied was 21± 3. Maximum ETCO2 during CPR was 44 ± 4, (p &lt; 0.001 compared with initial ETCO2). There was ROSC in 9/12 patients: 3 patients with asystole did not have ROSC. Time from IPR application to ROSC was 16 ± 3 minutes. Systolic/diastolic blood pressures immediately after ROSC were 126 ±13/72 ± 8. O2 saturation at ROSC was 96 ± 1%. IPR was used in 8/9 patients post ROSC for 8 ± 3 min. There were no observed adverse events. Conclusion: Clinical application of IPR during CPR increased ETCO2 values and resulted in ROSC in 9/12 patients, providing first clinical proof-of-concept that this new non-invasive technology increases circulation during CPR. Based upon these positive data, further study of IPR in patients in cardiac arrest is warranted.
Phase IB/II Study of Lirilumab with Azacytidine (AZA) in Relapsed AML
Authors: Naval Daver, Prajwal Boddu, Guillermo Garcia-Manero, Farhad Ravandi, Elias J. Jabbour, Gautam Borthakur, Courtney D. DiNardo, Marina Konopleva, Naveen Pemmaraju, Tapan Kadia, Nitin Jain, Sherry Pierce, Wilmer Flores, Steven Kornblau, Nawar Hussain, Jing Ning, Graciela Nogueras González, Sreyashi Basu, Jorge E. Cortes, Padmanee Sharma, Hagop M. Kantarjian
Journal: Blood (2017)
Neurocysticercosis as an Eradicable Cause of Epilepsy
Authors: Hector H. Garcia, Armando E. Gonzalez, Robert H. Gilman
Journal: JAMA Neurology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Hepatitis C Virus Microelimination is Feasible During COVID-19 Pandemic in Centers for Addiction Treatment Users
Authors: S. Acosta-Lopez, E. R. Candelaria, L. G. S. Gutierrez, J. C. F. Molina, P. D. Ruiz, M. Lara, M. D. Martinez-Garcia, A. L. Ramos, D. R. Galloway, R. L. Gonzalez-Guerra, A. R. Perez, R. S. Darias, A. G. Rodriguez, T. D. Vilar, F. A. P. Hernandez
Journal: Journal of Hepatology (2021)
MO4-5 A multicenter retrospective study of Oncomine Dx Target Test multi-CDx system for genetic profiling of NSCLC: WJOG13019L
Authors: Kentaro Ito, Shinya Sakata, Kohei Otsubo, Atsushi Nakamura, Shunsuke Teraoka, Naohisa Matsumoto, Yoshimasa Shiraishi, Koji Haratani, Motohiro Tamiya, Satoshi Ikeda, Satoru Miura, Junko Tanizaki, Shota Omori, Hiroshige Yoshioka, Akito Hata, Hisako Yoshida, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Journal: Annals of Oncology (2021)
COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy
Authors: Markus Weckmann, Thomas Bahmer, Jannie Marie Sand, Sarah Rank Rønnow, Martin Pech, Cornelis Vermeulen, Alen Faiz, Diana Julie Leeming, Morten Asser Karsdal, Lars Lunding, Brian George G. Oliver, Michael Wegmann, Gudrun Ulrich-Merzenich, Uwe R. Juergens, Jannis Duhn, Yves Laumonnier, Olga Danov, Katherina Sewald, Ulrich Zissler, Marnix Jonker, Inke König, Gesine Hansen, Erika von Mutius, Oliver Fuchs, Anna-Maria Dittrich, Bianca Schaub, Christine Happle, Klaus F. Rabe, Maarten van de Berge, Janette Kay Burgess, Matthias Volkmar Kopp
Journal: European Respiratory Journal (2021)

Background Asthma is a heterogeneous syndrome substantiating the urgent requirement for endotype-specific biomarkers. Dysbalance of fibrosis and fibrolysis in asthmatic lung tissue leads to reduced levels of the inflammation-protective collagen 4 (COL4A3). Objective To delineate the degradation of COL4A3 in allergic airway inflammation and evaluate the resultant product as a biomarker for anti-IgE therapy response. Methods The serological COL4A3 degradation marker C4Ma3 (Nordic Bioscience, Denmark) and serum cytokines were measured in the ALLIANCE cohort (paediatric cases/controls: n=134/n=35; adult cases/controls: n=149/n=31). Exacerbation of allergic airway disease in mice was induced by sensitising to ovalbumin (OVA), challenge with OVA aerosol and instillation of poly(cytidylic-inosinic). Fulacimstat (chymase inhibitor; Bayer) was used to determine the role of mast cell chymase in COL4A3 degradation. Patients with cystic fibrosis (n=14) and cystic fibrosis with allergic bronchopulmonary aspergillosis (ABPA; n=9) as well as patients with severe allergic uncontrolled asthma (n=19) were tested for COL4A3 degradation. Omalizumab (anti-IgE) treatment was assessed using the Asthma Control Test. Results Serum levels of C4Ma3 were increased in asthma in adults and children alike and linked to a more severe, exacerbating allergic asthma phenotype. In an experimental asthma mouse model, C4Ma3 was dependent on mast cell chymase. Serum C4Ma3 was significantly elevated in cystic fibrosis plus ABPA and at baseline predicted the success of the anti-IgE therapy in allergic, uncontrolled asthmatics (diagnostic OR 31.5). Conclusion C4Ma3 levels depend on lung mast cell chymase and are increased in a severe, exacerbating allergic asthma phenotype. C4Ma3 may serve as a novel biomarker to predict anti-IgE therapy response.
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial
Authors: Tapan M Kadia, Patrick K Reville, Gautam Borthakur, Musa Yilmaz, Steven Kornblau, Yesid Alvarado, Courtney D Dinardo, Naval Daver, Nitin Jain, Naveen Pemmaraju, Nicholas Short, Sa A Wang, Rebecca S S Tidwell, Rabiul Islam, Marina Konopleva, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M Kantarjian
Journal: The Lancet Haematology (2021)
Abstract 15952: A Pilot Trial of CD34+ Cell Therapy in Heart Failure With Preserved Ejection Fraction
Authors: Bojan Vrtovec, Sabina Frljak, Martina Jaklic, Gregor Poglajen, Gregor Zemljic, Andraz Cerar, Francois Haddad, Joseph C Wu
Journal: Circulation (2017)

Introduction: Previous studies have demonstrated that cell therapy may improve diastolic parameters in heart failure. Hypothesis: We sought to investigate the effects of transendocardial CD34+ cell...
Finding Our Balance in the Asymmetry Debate
Authors: Kyle G. Fritz
Journal: The American Journal of Bioethics (2021)

This article refers to:Unjustified Asymmetry: Positive Claims of Conscience and Heartbeat BillsJustifying Positive Appeals to Conscience: The Debate We Can’t AvoidPutting the Asymmetry Debate in Its PlaceThe Wrong Argument for a Bad LawMedical Disobedience and the Conscientious Provision of Prohibited CareDoes Medicine Need to Accommodate Positive Conscientious Objections to Morally Self-Correct?Conscience Claims and Cost: Tribunals and the Asymmetry DebateJustified Asymmetries: Positive and Negative Claims to Conscience in Reproductive Health CareConscience Clauses and Ideological BiasWhat Makes Conscientious Refusals Concerning Abortion Different
MO20-3 Real-world outcomes of surgery versus chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma
Authors: Kentaro Sawada, Hisashi Fujiwara, Hiroki Yukami, Saori Mishima, Daisuke Kotani, Tomohiro Kadota, Atsushi Inaba, Keiichiro Nishihara, Daiki Sato, Keiichiro Nakajo, Yusuke Yoda, Masaki Nakamura, Hidehiro Hojo, Tomonori Yano, Takeo Fujita, Takashi Kojima
Journal: Annals of Oncology (2021)
COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study
Authors: Luca Saverio Belli, Christophe Duvoux, Paolo Angelo Cortesi, Rita Facchetti, Speranta Iacob, Giovanni Perricone, Sylvie Radenne, Sara Conti, Damiano Patrono, Gabriela Berlakovich, Angus Hann, Luisa Pasulo, Lluis Castells, Francois Faitot, Olivier Detry, Federica Invernizzi, Giulia Magini, Paolo De Simone, Ilias Kounis, Maria Cristina Morelli, Fernando Díaz Fontenla, Bo-Göran Ericzon, Carmelo Loinaz, Chris Johnston, Liliana Gheorghe, Mickael Lesurtel, Renato Romagnoli, Dagmar Kollmann, M Thamara PR Perera, Stefano Fagiuoli, Darius Mirza, Audrey Coilly, Christian Toso, Krzysztof Zieniewicz, Laure Elkrief, Vincent Karam, Rene Adam, Caroline den Hoed, Marco Merli, Massimo Puoti, Luciano De Carlis, Gabriel C Oniscu, Salvatore Piano, Paolo Angeli, Constantino Fondevila, Wojciech G Polak
Journal: Gut (2021)

Objective Explore the impact of COVID-19 on patients on the waiting list for liver transplantation (LT) and on their post-LT course. Design Data from consecutive adult LT candidates with COVID-19 were collected across Europe in a dedicated registry and were analysed. Results From 21 February to 20 November 2020, 136 adult cases with laboratory-confirmed SARS-CoV-2 infection from 33 centres in 11 European countries were collected, with 113 having COVID-19. Thirty-seven (37/113, 32.7%) patients died after a median of 18 (10–30) days, with respiratory failure being the major cause (33/37, 89.2%). The 60-day mortality risk did not significantly change between first (35.3%, 95% CI 23.9% to 50.0%) and second (26.0%, 95% CI 16.2% to 40.2%) waves. Multivariable Cox regression analysis showed Laboratory Model for End-stage Liver Disease (Lab-MELD) score of ≥15 (Model for End-stage Liver Disease (MELD) score 15–19, HR 5.46, 95% CI 1.81 to 16.50; MELD score≥20, HR 5.24, 95% CI 1.77 to 15.55) and dyspnoea on presentation (HR 3.89, 95% CI 2.02 to 7.51) being the two negative independent factors for mortality. Twenty-six patients underwent an LT after a median time of 78.5 (IQR 44–102) days, and 25 (96%) were alive after a median follow-up of 118 days (IQR 31–170). Conclusions Increased mortality in LT candidates with COVID-19 (32.7%), reaching 45% in those with decompensated cirrhosis (DC) and Lab-MELD score of ≥15, was observed, with no significant difference between first and second waves of the pandemic. Respiratory failure was the major cause of death. The dismal prognosis of patients with DC supports the adoption of strict preventative measures and the urgent testing of vaccination efficacy in this population. Prior SARS-CoV-2 symptomatic infection did not affect early post-transplant survival (96%).
Investigating causality with fecal microbiota transplantation in rodents: applications, recommendations and pitfalls
Authors: Cassandra E. Gheorghe, Nathaniel L. Ritz, Jason A. Martin, Hannah R. Wardill, John F. Cryan, Gerard Clarke
Journal: Gut Microbes (2021)

In recent years, studies investigating the role of the gut microbiota in health and diseases have increased enormously – making it essential to deepen and question the research methodology employed. Fecal microbiota transplantation (FMT) in rodent studies (either from human or animal donors) allows us to better understand the causal role of the intestinal microbiota across multiple fields. However, this technique lacks standardization and requires careful experimental design in order to obtain optimal results. By comparing several studies in which rodents are the final recipients of FMT, we summarize the common practices employed. In this review, we document the limitations of this method and highlight different parameters to be considered while designing FMT Studies. Standardizing this method is challenging, as it differs according to the research topic, but avoiding common pitfalls is feasible. Several methodological questions remain unanswered to this day and we offer a discussion on issues to be explored in future studies.
Enhancing the Stabilization Potential of Lyophilization for Extracellular Vesicles
Authors: Eduard Trenkenschuh, Maximilian Richter, Eilien Heinrich, Marcus Koch, Gregor Fuhrmann, Wolfgang Friess
Journal: Advanced Healthcare Materials (2021)

Abstract Extracellular vesicles (EV) are an emerging technology as immune therapeutics and drug delivery vehicles. However, EVs are usually stored at −80 °C which limits potential clinical applicability. Freeze‐drying of EVs striving for long‐term stable formulations is therefore studied. The most appropriate formulation parameters are identified in freeze‐thawing studies with two different EV types. After a freeze‐drying feasibility study, four lyophilized EV formulations are tested for storage stability for up to 6 months. Freeze‐thawing studies revealed improved colloidal EV stability in presence of sucrose or potassium phosphate buffer instead of sodium phosphate buffer or phosphate‐buffered saline. Less aggregation and/or vesicle fusion occurred at neutral pH compared to slightly acidic or alkaline pH. EVs colloidal stability can be most effectively preserved by addition of low amounts of poloxamer 188. Polyvinyl pyrrolidone failed to preserve EVs upon freeze‐drying. Particle size and concentration of EVs are retained over 6 months at 40 °C in lyophilizates containing 10 m m K‐ or Na‐phosphate buffer, 0.02% poloxamer 188, and 5% sucrose. The biological activity of associated beta‐glucuronidase is maintained for 1 month, but decreased after 6 months. Here optimized parameters for lyophilization of EVs that contribute to generate long‐term stable EV formulations are presented.
Solid stress impairs lymphocyte infiltration into lymph-node metastases
Authors: Dennis Jones, Zixiong Wang, Ivy X. Chen, Sue Zhang, Rohin Banerji, Pin-Ji Lei, Hengbo Zhou, Victoria Xiao, Cecilia Kwong, Jan Willem M. van Wijnbergen, Ethel R. Pereira, Benjamin J. Vakoc, Peigen Huang, Hadi T. Nia, Timothy P. Padera
Journal: Nature Biomedical Engineering (2021)